Cargando…

Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment

The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the prevalence of HAT related sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Mudji, Junior, Blum, Anna, Grize, Leticia, Wampfler, Rahel, Ruf, Marie-Thérèse, Cnops, Lieselotte, Nickel, Beatrice, Burri, Christian, Blum, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157708/
https://www.ncbi.nlm.nih.gov/pubmed/31940846
http://dx.doi.org/10.3390/tropicalmed5010010
_version_ 1783522404306255872
author Mudji, Junior
Blum, Anna
Grize, Leticia
Wampfler, Rahel
Ruf, Marie-Thérèse
Cnops, Lieselotte
Nickel, Beatrice
Burri, Christian
Blum, Johannes
author_facet Mudji, Junior
Blum, Anna
Grize, Leticia
Wampfler, Rahel
Ruf, Marie-Thérèse
Cnops, Lieselotte
Nickel, Beatrice
Burri, Christian
Blum, Johannes
author_sort Mudji, Junior
collection PubMed
description The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the prevalence of HAT related signs and symptoms were evaluated before the start of treatment and at the end of treatment. To explore possible long-term sequelae, the same clinical parameters were assessed in 2017 in 51 first stage and 18 second stage HAT patients. Signs and symptoms 12–13 years after treatment were compared to before and immediately after treatment and to controls matched for sex and age (±5 years). In first stage HAT patients, the prevalence of all signs and symptoms decreased compared to before treatment but were still higher after 12–13 years than immediately at the end of treatment and in the control group. In second stage HAT patients, all HAT-specific findings had continuously decreased to the point where they were in the range of the healthy control group. In a selection of oligosymptomatic first stage HAT patients, no trypanosomes were detected in the blood by microscopic examination or PCR. An oligosymptomatic presentation of HAT due to the persistence of parasites in compartments, where first stage HAT medications do not penetrate, could not be ruled out.
format Online
Article
Text
id pubmed-7157708
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71577082020-04-21 Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment Mudji, Junior Blum, Anna Grize, Leticia Wampfler, Rahel Ruf, Marie-Thérèse Cnops, Lieselotte Nickel, Beatrice Burri, Christian Blum, Johannes Trop Med Infect Dis Article The clinical presentation of Human African Trypanosomiasis (HAT) due to Trypanosoma brucei gambiense is well known, but knowledge on long-term sequelae is limited. In the frame of studies conducted between 2004 and 2005 in the Democratic Republic of the Congo (DRC), the prevalence of HAT related signs and symptoms were evaluated before the start of treatment and at the end of treatment. To explore possible long-term sequelae, the same clinical parameters were assessed in 2017 in 51 first stage and 18 second stage HAT patients. Signs and symptoms 12–13 years after treatment were compared to before and immediately after treatment and to controls matched for sex and age (±5 years). In first stage HAT patients, the prevalence of all signs and symptoms decreased compared to before treatment but were still higher after 12–13 years than immediately at the end of treatment and in the control group. In second stage HAT patients, all HAT-specific findings had continuously decreased to the point where they were in the range of the healthy control group. In a selection of oligosymptomatic first stage HAT patients, no trypanosomes were detected in the blood by microscopic examination or PCR. An oligosymptomatic presentation of HAT due to the persistence of parasites in compartments, where first stage HAT medications do not penetrate, could not be ruled out. MDPI 2020-01-11 /pmc/articles/PMC7157708/ /pubmed/31940846 http://dx.doi.org/10.3390/tropicalmed5010010 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mudji, Junior
Blum, Anna
Grize, Leticia
Wampfler, Rahel
Ruf, Marie-Thérèse
Cnops, Lieselotte
Nickel, Beatrice
Burri, Christian
Blum, Johannes
Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
title Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
title_full Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
title_fullStr Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
title_full_unstemmed Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
title_short Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment
title_sort gambiense human african trypanosomiasis sequelae after treatment: a follow-up study 12 years after treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157708/
https://www.ncbi.nlm.nih.gov/pubmed/31940846
http://dx.doi.org/10.3390/tropicalmed5010010
work_keys_str_mv AT mudjijunior gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT blumanna gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT grizeleticia gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT wampflerrahel gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT rufmarietherese gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT cnopslieselotte gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT nickelbeatrice gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT burrichristian gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment
AT blumjohannes gambiensehumanafricantrypanosomiasissequelaeaftertreatmentafollowupstudy12yearsaftertreatment